Transradial arterial access to the rescue?

Thrombolytic therapy provides a beneficial treatment option for patients without contraindications who present with acute myocardial infarction (AMI) within 12 hours of symptom onset when the capability for primary percutaneous coronary intervention (PCI) within either 90 or 120 minutes of presentation is not possible (European Society of Cardiology [ESC], American College of Cardiology[ACC]/American Heart Association [AHA] Class Ia recommendation) [1,2]. Although there is obvious concern for increased bleeding, current guidelines from the ACC/AHA and ESC further support a strategy of early invasive management for both unstable (Class Ia) and stable (Class IIa) patients treated with thrombolytic therapy with timely transfer for catheterization/PCI [1,2].
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Tags: Editorial Source Type: research